Seagen and Genmab: Breakthrough Cervical Cancer Trial Outcome
- September 04th, 2023
- 242 views
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have reported a significant breakthrough in the Phase 3 innovaTV 301 global trial for recurrent or metastatic cervical cancer. Patients treated with TIVDAK (tisotumab vedotin-tftv) showed an improvement in overall survival (OS) compared to those receiving chemotherapy alone. An Independent Data Monitoring Committee found that OS exceeded the pre-specified efficacy threshold during interim analysis.
Additionally, key secondary endpoints, including progression-free survival and objective response rate, displayed statistically significant results. The safety profile of TIVDAK in the trial remained consistent with known information, with no new safety concerns.
On Friday, $SGEN closed at $207.91, gaining $1.84 (+0.89%), while $GMAB closed at $38.38, up $0.09 (+0.24%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login